{
    "clinical_study": {
        "@rank": "38627", 
        "acronym": "EW-1", 
        "arm_group": [
            {
                "arm_group_label": "Standard treatment (as per ISG SSG III protocol)", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard treatment for non metastatic Ewing's Sarcoma (as defined by the ISG/SSG III protocol).\nIt is based on a 6 drugs pre-local treatment (Vincristin, dactinomycin, cyclophosphamide,ifosfamide,etoposide and doxorubicin) followed by local treatment (surgery and/or radiotherapy)and by a maintenance treatment based on induction response"
            }, 
            {
                "arm_group_label": "Intensified treatment", 
                "arm_group_type": "Experimental", 
                "description": "Dose intense treatment for non metastatic Ewing's Sarcoma It is based on a 3 drug pre-local treatment (Vincristin, ifosfamide and doxorubicin)followed by local treatment (surgery and/or radiotherapy)and by a maintenance treatment based on induction response"
            }
        ], 
        "brief_summary": {
            "textblock": "Controlled, randomized phase III study, with the intent of optimizing the treatment of not\n      metastatic Ewing Sarcoma. The patients will be randomized into 2 arms: standard treatment vs\n      intensive treatment. Both arms will receive an induction treatment followed by surgery\n      (wherever is possible) and/or radiotherapy. The maintenance treatment will be different on\n      the basis of the response to the induction treatment (good or poor)"
        }, 
        "brief_title": "Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Ewing's Sarcoma", 
        "condition_browse": {
            "mesh_term": [
                "Sarcoma, Ewing's", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Eligible patients with non metastatic Ewing's Sarcoma will be randomized into 2 different\n      arms: standard treatment arm A (based on the ISG/SSG III protocol) or into the experimental\n      arm B(chemotherapy with dose intensification and shorter length of treatment).\n\n      Both arm will receive an induction treatment with higher dose intensity of doxorubicin and\n      ifosfamide in Arm B.\n\n      After the induction treatment all the patient will undergo to local treatment (surgery\n      and/or radiotherapy)that will be followed by a maintenance therapy.\n\n      The maintenance therapy will be different for both arms and, within each arm, on the basis\n      of the response (histologically evaluated) of the pre-local treatment therapy.\n\n      Maintenance for Arm A: Poor responders will undergo to stem cells apheresis and their\n      reinfusion after treatment with high doses of Busulfan and Melphalan 25 weeks.\n\n      Good responders will receive a 6 drugs maintenance treatment for 37 weeks (as per standard\n      ISG/SSG III protocol)\n\n      Maintenance for Arm B: Poor responders will undergo to stem cells apheresis and their\n      reinfusion after an intensified treatment with high doses of Busulfan and Melphalan (25\n      weeks).\n\n      Good responders will receive a maintenance treatment for 25 weeks\n\n      The primary aim of the study is to assess the Event Free Survival (EFS) that is expected to\n      be similar in both arms\n\n      The secondary objectives are:\n\n      To assess if the induction treatment in Arm B is able to increase the percentage of good\n      responders compared to those who receive standard treatment.\n\n      To assess the toxicity and the Quality of Life related to the chemotherapy treatment"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Ewing Sarcoma or PNET diagnosis centrally confirmed\n\n          -  Age \u2264 40 years\n\n          -  Absence of evident metastasis or lung met < 0.5 cm Presence of skip metastasis in the\n             bone compartment of the primary tumor is to be considered as local disease and not\n             metastatic.\n\n          -  Adeguate bone marrow, hepatic and renal function\n\n          -  Left Ventricular Ejection Fraction > 50%\n\n          -  No primary Ewing Sarcoma treatments (both chemotherapy and/or radiotherapy)\n\n          -  Voluntarily signed an informed consent form\n\n          -  Radiological and histological documentation available for central review.\n\n        Exclusion Criteria\n\n          -  Presence of lung or extra-pulmonary lesions\n\n          -  Bone Marrow involvement\n\n          -  In case of chest disease: presence of plural effusion\n\n          -  Elapsed time between histological diagnosis and chemotherapy start, more than 4 weeks\n\n          -  Any medical contraindication to the use of the study drugs\n\n          -  Any psychological or social conditions that can compromise the protocol compliance\n             and/or follow-up\n\n          -  Previous malignancies (excluded in situ cervix carcinoma)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "220", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02063022", 
            "org_study_id": "ISG/AIEOP EW-1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Standard treatment (as per ISG SSG III protocol)", 
                "description": "Induction treatment with: 4 cycle of Vincristine (9mg/,2), Dactinomycin (6mg/m2), Doxorubicin (160mg/m2), Cyclophosphamide (2.4g/m2), Ifosfamide (18g/M2) and Etoposide (450mg/m2) given every 3 weeks Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Dactinomycin (1.5mg/m2), Doxorubicin (320mg/m2), Ifosfamide (27g/m2), Cyclophosphamide (8.8g/m2), Etoposide (1.5g/m2) and peripheral Cells Steam Transplant after Busulfan and Melphalan treatment Maintenance treatment (37 week) for good responder: Vincristine (18mg/m2), Dactinomycin (6mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Cyclosphosphamide(6g/m2), Etoposide (1.8 g/m2)", 
                "intervention_name": "Standard treatment (as per protocol ISG SSG III)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Vincristine", 
                    "Dactinomycin", 
                    "Doxorubicin", 
                    "Ifosfamide", 
                    "Cyclophosphamide", 
                    "Etoposide", 
                    "Busulfan", 
                    "Melphalan"
                ]
            }, 
            {
                "arm_group_label": "Intensified treatment", 
                "description": "Induction treatment with: 4 cycle of Vincristine (10.5 mg/m2), Doxorubicin (320 mg/m2) and Ifosfamide (36 mg/m2) given every 3 weeks\nMaintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (63g/m2), Cyclophosphamide (4g/m2), Etoposide (1.5g/m2) and Cells Steam Transplant after Busulfan and Melphalan treatment\nMaintenance treatment (25 week) for good responder: Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Etoposide (1.8g/m2)", 
                "intervention_name": "Intensified chemotherapy", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Vincristine,", 
                    "Doxorubicin", 
                    "Ifosfamide", 
                    "Cyclophosphamide", 
                    "Etoposide", 
                    "Busulfan", 
                    "Melphalan"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dactinomycin", 
                "Doxorubicin", 
                "Etoposide phosphate", 
                "Isophosphamide mustard", 
                "Busulfan", 
                "Cyclophosphamide", 
                "Etoposide", 
                "Ifosfamide", 
                "Melphalan", 
                "Vincristine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Non metastatic Ewing's Sarcoma", 
        "lastchanged_date": "February 13, 2014", 
        "link": {
            "description": "Italian protocol Synopsis", 
            "url": "http://www.italiansarcomagroup.org/protocolli/Sinossi.prot.ISG.EW.1.pdf"
        }, 
        "location": [
            {
                "contact": {
                    "email": "mascarin@cro.it", 
                    "last_name": "Maurizio Mascarin, MD", 
                    "phone": "+390434659", 
                    "phone_ext": "536"
                }, 
                "contact_backup": {
                    "email": "mascarin@cro.it", 
                    "last_name": "Maurizio Mascarin, MD", 
                    "phone": "+390434659"
                }, 
                "facility": {
                    "address": {
                        "city": "Aviano", 
                        "country": "Italy", 
                        "state": "Pordenone", 
                        "zip": "33081"
                    }, 
                    "name": "Centro di Riferimento Oncologico - Unit of Medical Oncology"
                }, 
                "investigator": {
                    "last_name": "Maurizio Mascarin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "massimo.aglietta@ircc.it", 
                    "last_name": "Massimo Aglietta, MD", 
                    "phone": "+39.011.9933", 
                    "phone_ext": "628"
                }, 
                "contact_backup": {
                    "email": "luisa.gioeni@ircc.it", 
                    "last_name": "Luisa Gioeni, Pharmacist", 
                    "phone": "+39.011.9933", 
                    "phone_ext": "278"
                }, 
                "facility": {
                    "address": {
                        "city": "Candiolo", 
                        "country": "Italy", 
                        "state": "Torino", 
                        "zip": "10060"
                    }, 
                    "name": "I.R.C.C. - Unit of Medical Oncology"
                }, 
                "investigator": [
                    {
                        "last_name": "Massimo Aglietta, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Giovanni Grignani, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "alessandro.comandone@gradenigo.it", 
                    "last_name": "Alessandro Comandone, MD", 
                    "phone": "+390118151", 
                    "phone_ext": "211"
                }, 
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy", 
                        "state": "TO", 
                        "zip": "10153"
                    }, 
                    "name": "Presidio Sanitario Gradenigo"
                }, 
                "investigator": {
                    "last_name": "Alessandro Comandone, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tmoped@aosp.bo.it", 
                    "last_name": "Arcangelo Prete, MD", 
                    "phone": "+390516363", 
                    "phone_ext": "111"
                }, 
                "facility": {
                    "address": {
                        "city": "Bologna", 
                        "country": "Italy", 
                        "zip": "40138"
                    }, 
                    "name": "A.O. Universitaria Policlinico S. Orsola Malpighi di Bologna"
                }, 
                "investigator": {
                    "last_name": "Arcangelo Prete, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "stefano.ferrari@ior.it", 
                    "last_name": "Stefano Ferrari, MD", 
                    "phone": "+390516366", 
                    "phone_ext": "411"
                }, 
                "contact_backup": {
                    "email": "emanuela.marchesi@ior.it", 
                    "last_name": "Emanuela Marchesi, PhD", 
                    "phone": "+390516366", 
                    "phone_ext": "400"
                }, 
                "facility": {
                    "address": {
                        "city": "Bologna", 
                        "country": "Italy", 
                        "zip": "40136"
                    }, 
                    "name": "Istituto Ortopedico Rizzoli"
                }, 
                "investigator": {
                    "last_name": "Stefano Ferrari, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Rosamaria Mura, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Cagliari", 
                        "country": "Italy", 
                        "zip": "Rosamaria"
                    }, 
                    "name": "Servizio di Oncoematologi Pediatrica Ospedale microcitemico ASL 8"
                }, 
                "investigator": {
                    "last_name": "Rosamaria Mura, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "a.tamburini@meyer.it", 
                    "last_name": "Angela Tamburini, MD", 
                    "phone": "+3905556", 
                    "phone_ext": "621"
                }, 
                "facility": {
                    "address": {
                        "city": "Firenze", 
                        "country": "Italy", 
                        "zip": "50139"
                    }, 
                    "name": "A.O. Universitaria Meyer"
                }, 
                "investigator": {
                    "last_name": "Angela Tamburini, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "albertogaraventa@ospedale-gaslini.ge.it", 
                    "last_name": "Alberto Garaventa, MD", 
                    "phone": "+390105636", 
                    "phone_ext": "694"
                }, 
                "facility": {
                    "address": {
                        "city": "Genova", 
                        "country": "Italy"
                    }, 
                    "name": "Istituto Giannina Gaslini"
                }, 
                "investigator": {
                    "last_name": "Alberto Garaventa, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Roberto Luksch, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy"
                    }, 
                    "name": "FONDAZIONE IRCCS Istituto Nazionale dei Tumori"
                }, 
                "investigator": {
                    "last_name": "Roberto Luksch, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gianni Bisogno, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda Ospedaliera di Padova"
                }, 
                "investigator": {
                    "last_name": "Gianni Bisogno, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Raffaele Cozza, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale Pediatrico Bambin Gesu'"
                }, 
                "investigator": {
                    "last_name": "Raffaele Cozza, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ferraresi@ifo.it", 
                    "last_name": "Virginia Ferraresi, MD", 
                    "phone": "+390652666", 
                    "phone_ext": "773"
                }, 
                "contact_backup": {
                    "last_name": ", MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "zip": "00144"
                    }, 
                    "name": "Istituto Nazionale Tumori Regina Elena - Unit of Medical Oncology I"
                }, 
                "investigator": {
                    "last_name": "Virginia Ferraresi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "franca.fagioli@unito.it", 
                    "last_name": "Franca Fagioli, MD", 
                    "phone": "+39.011.3135", 
                    "phone_ext": "230"
                }, 
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy", 
                        "zip": "10126"
                    }, 
                    "name": "Ospedale Infantile Regina Margherita - Unit of Paediatric Oncoematology"
                }, 
                "investigator": {
                    "last_name": "Franca Fagioli, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase III Study on Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma.", 
        "overall_contact": {
            "email": "stefano.ferrari@ior.it", 
            "last_name": "Stefano Ferrari, MD", 
            "phone": "+390516366", 
            "phone_ext": "4111"
        }, 
        "overall_contact_backup": {
            "email": "piero.picci@ior.it", 
            "last_name": "Piero Picci, MD", 
            "phone": "+390516366", 
            "phone_ext": "6759"
        }, 
        "overall_official": {
            "affiliation": "Italian Sarcoma Group", 
            "last_name": "Stefano Ferrari, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The EFS (event defined as Progressive Disease , onset of local relapse and/or metastasis, death due to chemotherapy toxicity or for other causes) will be calculated from the first treatment day up to the event onset or to last follow-up", 
            "measure": "Event Free Survival (EFS)", 
            "safety_issue": "Yes", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02063022"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The DFS will be calculated from the day that the patient will be free from disease (surgery date and/or radiotherapy completion) up to the date of progression disease or last follow-up", 
                "measure": "Disease Free Survival (DFS)", 
                "safety_issue": "No", 
                "time_frame": "expected average 3 years"
            }, 
            {
                "description": "The Metastasis free Survival will be evaluated from the time of disease free (surgery performed and/or radiotherapy completed) to the onset of distance metastasis or last follow-up", 
                "measure": "Metastasis Free Survival", 
                "safety_issue": "No", 
                "time_frame": "expected average 2 years"
            }, 
            {
                "description": "The OS will be evaluated for the start treatment day to the day of death (for any causes)", 
                "measure": "Overall Survival (OS)", 
                "safety_issue": "Yes", 
                "time_frame": "expected average 5 years"
            }
        ], 
        "source": "Italian Sarcoma Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Italian Sarcoma Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}